{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:46:32Z","timestamp":1793411192364,"version":"4.5.0"},"reference-count":226,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.neuropharm.2023.109815","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T01:28:35Z","timestamp":1702776515000},"page":"109815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6933-5675","authenticated-orcid":false,"given":"Matteo","family":"Carpi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1676-629X","authenticated-orcid":false,"given":"Laura","family":"Palagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7005-2805","authenticated-orcid":false,"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-7281","authenticated-orcid":false,"given":"Carmen","family":"Calvello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9121-209X","authenticated-orcid":false,"given":"Pierre Alexis","family":"Geoffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7536-9927","authenticated-orcid":false,"given":"Mario","family":"Miniati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-9144","authenticated-orcid":false,"given":"Stefano","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-874X","authenticated-orcid":false,"given":"Angelo","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-7491","authenticated-orcid":false,"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-1332","authenticated-orcid":false,"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109815_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smrv.2015.05.007","article-title":"Sleep disorders and respiratory function in amyotrophic lateral sclerosis","volume":"26","author":"Ahmed","year":"2016","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13651501.2019.1711425","article-title":"Orexin A in adolescents with anxiety disorders","volume":"24","author":"Ak\u00e7a","year":"2020","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2023.109815_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.conb.2013.04.008","article-title":"Control of arousal by the orexin neurons","volume":"23","author":"Alexandre","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/bc.bc_42_19","article-title":"Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circ"},{"key":"10.1016\/j.neuropharm.2023.109815_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1212\/WNL.59.4.639","article-title":"Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome","volume":"59","author":"Allen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11920-016-0728-8","article-title":"Sleep and eating disorders","volume":"18","author":"Allison","year":"2016","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib7","series-title":"Diagnostic and Statistical Manual of Mental Disorders, DSM-5-TR","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109815_bib8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system\u201440 years and counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fnins.2020.00636","article-title":"Disrupted sleep and circadian rhythms in schizophrenia and their interaction with dopamine signaling","volume":"14","author":"Ashton","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib10","series-title":"Brain Pathol. 0, 080522015037583-???","article-title":"Hypocretin and melanin-concentrating hormone in patients with Huntington disease","author":"Aziz","year":"2008"},{"key":"10.1016\/j.neuropharm.2023.109815_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000079749","article-title":"Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness","volume":"52","author":"Baumann","year":"2004","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib12","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1523\/JNEUROSCI.3388-13.2014","article-title":"Acute suppressive and long-term phase modulation actions of orexin on the mammalian circadian clock","volume":"34","author":"Belle","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s40263-020-00768-8","article-title":"Pharmacological interactions between the dual orexin receptor antagonist daridorexant and ethanol in a double-blind, randomized, placebo-controlled, double-dummy, four-way crossover phase I study in healthy subjects","volume":"34","author":"Berger","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172929","article-title":"Orexins role in neurodegenerative diseases: from pathogenesis to treatment","volume":"194","author":"Berhe","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109815_bib15","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/epi.17661","article-title":"Role of the orexin system in the bidirectional relation between sleep and epilepsy: new chances for patients with epilepsy by the antagonism to orexin receptors?","volume":"64","author":"Berteotti","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2023.109815_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/ejn.15077","article-title":"Dysregulation of the orexin\/hypocretin system is not limited to narcolepsy but has far\u2010reaching implications for neurological disorders","volume":"53","author":"Berteotti","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib17","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1468-2982.2006.01166.x","article-title":"The natural history of headache: predictors of onset and recovery","volume":"26","author":"Boardman","year":"2006","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/NSS.S183504","article-title":"Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives","volume":"11","author":"Boentert","year":"2019","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib19","doi-asserted-by":"crossref","first-page":"zsaa275","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Boof","year":"2021","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2018.12.025","article-title":"Sleep deprivation-induced pre- and postsynaptic modulation of orexin neurons","volume":"154","author":"Briggs","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainresbull.2022.05.002","article-title":"Translational approaches to influence sleep and arousal","volume":"185","author":"Brown","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2023.109815_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00330","article-title":"Sleep disorders associated with Alzheimer's disease: a perspective","author":"Brzecka","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11154-013-9259-3","article-title":"Orexin: pathways to obesity resistance?","volume":"14","author":"Butterick","year":"2013","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.neuropharm.2023.109815_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2014.03.043","article-title":"Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization","volume":"269","author":"Cady","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109815_bib25","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study","volume":"22","author":"Camargos","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109815_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.08.005","article-title":"A sleeping giant: suvorexant for the treatment of alcohol use disorder?","volume":"1731","author":"Campbell","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib27","series-title":"Behavioral Neuroscience of Orexin\/Hypocretin, Current Topics in Behavioral Neurosciences","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/7854_2016_46","article-title":"Orexin and central modulation of cardiovascular and respiratory function","author":"Carrive","year":"2016"},{"key":"10.1016\/j.neuropharm.2023.109815_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smrv.2016.08.001","article-title":"A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015","volume":"35","author":"Chahine","year":"2017","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101583","article-title":"Sleep and anxiety: from mechanisms to interventions","volume":"61","author":"Chellappa","year":"2022","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/med.21326","article-title":"The hypocretin\/orexin system: an increasingly important role in neuropsychiatry: the hypocretin\/orexin system in neuropsychiatry","volume":"35","author":"Chen","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13021","article-title":"Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: a randomized, double\u2010blind, placebo\u2010controlled, crossover study","volume":"29","author":"Cheng","year":"2020","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib33","first-page":"81","article-title":"The hypocretin\/orexin system in sleep disorders: preclinical insights and clinical progress","volume":"8","author":"Chow","year":"2016","journal-title":"Nat. Sci. Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib34","doi-asserted-by":"crossref","DOI":"10.2165\/00023210-200822110-00004","article-title":"Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics","author":"Cohrs","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib35","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awp263","article-title":"Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia","volume":"132","author":"Compta","year":"2009","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","article-title":"Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder","volume":"20","author":"Connor","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib37","doi-asserted-by":"crossref","first-page":"pyw022","DOI":"10.1093\/ijnp\/pyw022","article-title":"A phase II dose-ranging study evaluating the efficacy and safety of the orexin receptor antagonist filorexant (MK-6096) in patients with primary insomnia","volume":"19","author":"Connor","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib38","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3389\/fphar.2019.00695","article-title":"Sleep and \u03b2-amyloid deposition in alzheimer disease: insights on mechanisms and possible innovative treatments","volume":"10","author":"Cordone","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1468-2982.2003.00343.x","article-title":"Increased frequency of migraine in narcoleptic patients: a confirmatory study","volume":"23","author":"Dahmen","year":"2003","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib40","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1212\/WNL.52.6.1291","article-title":"Increased frequency of migraine in narcoleptic patients","volume":"52","author":"Dahmen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1389-9457(08)70006-6","article-title":"Insomnia in patients with neurodegenerative conditions","volume":"8","author":"Dauvilliers","year":"2007","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fphar.2014.00016","article-title":"Hypocretin (orexin) regulation of sleep-to-wake transitions","volume":"5","author":"de Lecea","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109815_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neuroscience.2004.07.049","article-title":"Convergence of circadian and sleep regulatory mechanisms on hypocretin-1","volume":"129","author":"Deboer","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109815_bib45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrn2762","article-title":"The memory function of sleep","volume":"11","author":"Diekelmann","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib46","first-page":"1104","article-title":"Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994. Addict","volume":"112","author":"Dolsen","year":"2017","journal-title":"Abingdon Engl"},{"key":"10.1016\/j.neuropharm.2023.109815_bib47","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00228-022-03381-4","article-title":"Daridorexant for the treatment of insomnia disorder: findings and implications","volume":"78","author":"dos Santos","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1532-5415.2007.01543.x","article-title":"Melatonin and bright-light treatment for rest\u2013activity disruption in institutionalized patients with Alzheimer's disease: melatonin and light therapy in ALZHEIMER\u2019S disease","volume":"56","author":"Dowling","year":"2008","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.neuropharm.2023.109815_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","volume":"61","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nlm.2018.06.009","article-title":"Bidirectional relationships between sleep and amyloid-beta in the hippocampus","volume":"160","author":"Dufort-Gervais","year":"2019","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2023.109815_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109815_bib52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jnnp.2006.104034","article-title":"The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration","volume":"78","author":"Ellul","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109815_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2013.00163","article-title":"Orexin receptor antagonists as therapeutic agents for insomnia","volume":"4","author":"Equihua","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib54","article-title":"Orexin receptor antagonists in the treatment of depression: a leading article summarising pre-clinical and clinical studies","author":"Fagan","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.1085882","article-title":"Alternative use of suvorexant (Belsomra\u00ae) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence","volume":"16","author":"Flores-Ramirez","year":"2022","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib56","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson's disease","volume":"130","author":"Fronczek","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2023.109815_bib57","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.neurobiolaging.2011.03.014","article-title":"Hypocretin (orexin) loss in Alzheimer's disease","volume":"33","author":"Fronczek","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2023.109815_bib58","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/nan.12709","article-title":"Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis","volume":"47","author":"Gabery","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib59","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/sleep\/28.12.1607","article-title":"CSF hypocretin levels are normal in Huntington's disease patients","volume":"28","author":"Gaus","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/JGP.0b013e318187de18","article-title":"Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease","volume":"17","author":"Gehrman","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2023.109815_bib61","first-page":"S31","article-title":"Perspectives on the management of insomnia in patients with chronic respiratory disorders","volume":"23","author":"George","year":"2000","journal-title":"Sleep"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2023.109815_bib62","first-page":"S27","article-title":"Epilepsy and common comorbidities: improving the outpatient epilepsy encounter","volume":"7","author":"Gilliam","year":"2005","journal-title":"Epileptic Disord. Int. Epilepsy J. Videotape"},{"key":"10.1016\/j.neuropharm.2023.109815_bib63","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/0333102414566196","article-title":"Putting migraine to sleep: rexants as a preventive strategy","volume":"35","author":"Goadsby","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2023.109815_bib64","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-022-02090-x","article-title":"Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety","volume":"12","author":"Gorka","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109815_bib65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41398-019-0415-8","article-title":"Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder\/agoraphobia, CBT treatment response and fear-related intermediate phenotypes","volume":"9","author":"Gottschalk","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109815_bib66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/MCP.0000000000000101","article-title":"Sleep disorders in adults with epilepsy: past, present, and future directions","volume":"20","author":"Grigg-Damberger","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib67","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/0002-9343(90)90282-I","article-title":"Benzodiazepines, breathing, and sleep","volume":"88","author":"Guilleminault","year":"1990","journal-title":"Am. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib68","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/01616412.2017.1352185","article-title":"The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson's disease","volume":"39","author":"Hadadianpour","year":"2017","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib69","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-022-00918-0","article-title":"Dual orexin receptor antagonists (DORAs) as an adjunct treatment for smoking cessation","volume":"36","author":"Hamidovic","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib70","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin receptor antagonists as emerging treatments for psychiatric disorders","volume":"36","author":"Han","year":"2020","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuropharm.2023.109815_bib71","doi-asserted-by":"crossref","first-page":"547","DOI":"10.9758\/cpn.2019.17.4.547","article-title":"Effect of suvorexant on nocturnal delirium in elderly patients with Alzheimer's disease: a case-series study","volume":"17","author":"Hanazawa","year":"2019","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib72","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2377-12-82","article-title":"Precipitating and relieving factors of migraine versus tension type headache","volume":"12","author":"Haque","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib73","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.tins.2006.08.002","article-title":"Arousal and reward: a dichotomy in orexin function","volume":"29","author":"Harris","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib74","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109815_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","author":"Herring","year":"2020","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"10.1016\/j.neuropharm.2023.109815_bib76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.smrv.2018.10.006","article-title":"Insomnia as a predictor of mental disorders: a systematic review and meta-analysis","volume":"43","author":"Hertenstein","year":"2019","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib77","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fpsyt.2019.00221","article-title":"Sleep disorders in Huntington's disease","volume":"10","author":"Herzog\u2013Krzywoszanska","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109815_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","article-title":"Evidence for orexinergic mechanisms in migraine","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib79","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1526-4610.2007.00842.x","article-title":"The hypothalamic orexinergic system: pain and primary headaches","volume":"47","author":"Holland","year":"2007","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.neuropharm.2023.109815_bib80","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","article-title":"Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat","volume":"24","author":"Holland","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib81","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/jpet.105.090951","article-title":"Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception","volume":"315","author":"Holland","year":"2005","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109815_bib82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neubiorev.2014.12.005","article-title":"Roles of the orexin system in central motor control","volume":"49","author":"Hu","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1127735","article-title":"Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats","volume":"14","author":"Illenberger","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib84","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/17512433.2014.966813","article-title":"Suvorexant for the treatment of insomnia","volume":"7","author":"Jacobson","year":"2014","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib85","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2022.06.027","article-title":"Orexin reserve: a mechanistic framework for the role of orexins (hypocretins) in addiction","volume":"92","author":"James","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109815_bib86","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0080-2019","article-title":"Management of insomnia in sleep disordered breathing","volume":"28","author":"Janssen","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib87","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.5664\/jcsm.7282","article-title":"An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics","volume":"14","author":"Janto","year":"2018","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib88","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.neuropharm.2023.109815_bib89","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-444-59489-1.00009-4","article-title":"Orexin, stress, and anxiety\/panic states","volume":"198","author":"Johnson","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib91","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid-\u03b2 dynamics are regulated by orexin and the sleep-wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109815_bib92","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/sleep\/32.9.1127","article-title":"Orexin neurons are necessary for the circadian control of REM sleep","volume":"32","author":"Kantor","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.brainresbull.2022.05.006","article-title":"Sleep-wake and arousal dysfunctions in post-traumatic stress disorder: role of orexin systems","volume":"186","author":"Kaplan","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2023.109815_bib94","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/brainsci12020150","article-title":"Neurobiology of the orexin system and its potential role in the regulation of hedonic tone","volume":"12","author":"Katzman","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib95","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1526-4610.2005.05159.x","article-title":"Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs","volume":"45","author":"Kelman","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib96","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neubiorev.2020.07.040","article-title":"Dysregulation of the orexinergic system: a potential neuropeptide target in depression","volume":"118","author":"Khairuddin","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib97","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40263-014-0179-x","article-title":"Orexin\/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?","volume":"28","author":"Khoo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib98","first-page":"28","article-title":"Comorbid insomnia and psychiatric disorders: an update","volume":"15","author":"Khurshid","year":"2018","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib99","first-page":"237","article-title":"Clinical implication of REM sleep behavior disorder in Parkinson's disease","volume":"4","author":"Kim","year":"2014","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/npr2.12069","article-title":"Suvorexant for insomnia in patients with psychiatric disorder: a 1-week, open-label study","volume":"39","author":"Kishi","year":"2019","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib101","series-title":"The Abstract of Japanese Society of Sleep Research Meeting 192","article-title":"Treatment strategies when multiple sleep disturbances coexist","author":"Kotorii","year":"2015"},{"key":"10.1016\/j.neuropharm.2023.109815_bib102","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pharep.2015.09.002","article-title":"Emerging role of orexin antagonists in insomnia therapeutics: an update on SORAs and DORAs","volume":"68","author":"Kumar","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib103","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/sleep\/28.4.499","article-title":"Practice parameters for the indications for polysomnography and related procedures: an update for 2005","volume":"28","author":"Kushida","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib104","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/WNR.0b013e32833bfb7c","article-title":"Reduced hypocretin (orexin) levels in dementia with Lewy bodies","volume":"21","author":"Lessig","year":"2010","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2023.109815_bib105","article-title":"Increased hypocretin (orexin) plasma level in depression, bipolar disorder patients","volume":"12","author":"Li","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109815_bib106","article-title":"Plasma orexin-A levels in patients with schizophrenia: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109815_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2023.101762","article-title":"The evolving role of quantitative actigraphy in clinical sleep medicine","volume":"68","author":"Liguori","year":"2023","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2016.01.007","article-title":"Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease","author":"Liguori","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2023.109815_bib109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-019-0918-y","article-title":"CSF biomarkers for early diagnosis of synucleinopathies: focus on idiopathic RBD","volume":"19","author":"Liguori","year":"2019","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib110","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2014.2510","article-title":"Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease","author":"Liguori","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib111","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jnc.14568","article-title":"Orexins increase the firing activity of nigral dopaminergic neurons and participate in motor control in rats","volume":"147","author":"Liu","year":"2018","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109815_bib112","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/0366-6999.149214","article-title":"Increased orexin expression promotes sleep\/wake disturbances in the SOD1-G93A mouse model of amyotrophic lateral sclerosis","volume":"128","author":"Liu","year":"2015","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.neuropharm.2023.109815_bib113","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.26641","article-title":"Suvorexant acutely decreases tau phosphorylation and a\u03b2 in the human CNS","volume":"94","author":"Lucey","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib114","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eplepsyres.2017.05.014","article-title":"Insomnia in people with epilepsy: a review of insomnia prevalence, risk factors and associations with epilepsy-related factors","volume":"135","author":"Mac\u00eado","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz302","article-title":"Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice","volume":"43","author":"Mahoney","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib116","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1535-7597.2004.04509.x","article-title":"Sleep deprivation and epilepsy","volume":"4","author":"Malow","year":"2004","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.neuropharm.2023.109815_bib117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1389-9457(99)00008-8","article-title":"Localizing value of rapid eye movement sleep in temporal lobe epilepsy","volume":"1","author":"Malow","year":"2000","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib118","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tins.2016.05.002","article-title":"Sleep: a novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer's disease?","volume":"39","author":"Mander","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib119","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eplepsyres.2010.05.006","article-title":"Comorbidity between epilepsy and sleep disorders","volume":"90","author":"Manni","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib120","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.5665\/sleep.3142","article-title":"Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography","volume":"36","author":"Marino","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib121","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-6606-1-19","article-title":"Circadian and dark-pulse activation of orexin\/hypocretin neurons","volume":"1","author":"Marston","year":"2008","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2023.109815_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011090.pub2","article-title":"Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea","author":"Mason","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib124","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/archneur.1965.00470030090009","article-title":"Electroencephalograms of epileptics following sleep deprivation","volume":"13","author":"Mattson","year":"1965","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s42466-021-00106-3","article-title":"Insomnia in neurological diseases","volume":"3","author":"Mayer","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"10.1016\/j.neuropharm.2023.109815_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2011.01.005","article-title":"Insomnia in central neurologic diseases \u2013 occurrence and management","author":"Mayer","year":"2011","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib127","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1053\/smrv.2000.0127","article-title":"Treatment of sleep disturbance in Alzheimer's disease","volume":"4","author":"McCurry","year":"2000","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib128","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41386-021-01052-z","article-title":"Sleep dysregulation in binge eating disorder and \u201cfood addiction\u201d: the orexin (hypocretin) system as a potential neurobiological link","volume":"46","author":"Mehr","year":"2021","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2015.01.067","article-title":"REM sleep loss associated changes in orexin-A levels in discrete brain areas in rats","volume":"590","author":"Mehta","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109815_bib130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2005.09.028","article-title":"Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease","volume":"1063","author":"Meier","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib131","doi-asserted-by":"crossref","first-page":"zsac068","DOI":"10.1093\/sleep\/zsac068","article-title":"Evaluation of suvorexant for trauma-related insomnia","volume":"45","author":"Mellman","year":"2022","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2014.00997","article-title":"Orexin-A controls sympathetic activity and eating behavior","volume":"5","author":"Messina","year":"2014","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib133","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40263-012-0036-8","article-title":"Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status","volume":"27","author":"Mieda","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.113976","article-title":"Etiologies of insomnia in Parkinson's disease \u2013 lessons from human studies and animal models","volume":"350","author":"Mizrahi-Kliger","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib136","first-page":"1","article-title":"Safety and efficacy of lemborexant in patients with irregular sleep-wake rhythm disorder and Alzheimer's disease dementia: results from a phase 2 randomized clinical trial","volume":"8","author":"Moline","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib137","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/sleep\/30.4.519","article-title":"Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib138","article-title":"Insomnia disorder","volume":"1","author":"Morin","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2023.109815_bib139","first-page":"30","article-title":"Neuroendocrine, autonomic, and metabolic responses to an orexin antagonist, suvorexant, in psychiatric patients with insomnia","volume":"14","author":"Nakamura","year":"2017","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21550","article-title":"Orexin supplementation in narcolepsy treatment: a review","volume":"39","author":"Nepovimova","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib141","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsw061","article-title":"Orexin and epilepsy: potential role of REM sleep","volume":"40","author":"Ng","year":"2017","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib142","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1748-1716.2009.02012.x","article-title":"Hypocretin\/orexin and narcolepsy: new basic and clinical insights","volume":"198","author":"Nishino","year":"2010","journal-title":"Acta Physiol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib143","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2023.109815_bib144","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/j.1528-1167.2011.03198.x","article-title":"Lateralized interictal epileptiform discharges during rapid eye movement sleep correlate with epileptogenic hemisphere in children with intractable epilepsy secondary to tuberous sclerosis complex: lateralized IEDs in REM Sleep in TSC Children","volume":"52","author":"Ochi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2023.109815_bib145","author":"Olsson"},{"key":"10.1016\/j.neuropharm.2023.109815_bib146","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jsmc.2013.04.004","article-title":"Insomnia and obstructive sleep apnea","volume":"8","author":"Ong","year":"2013","journal-title":"Sleep Med. Clin."},{"key":"10.1016\/j.neuropharm.2023.109815_bib147","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.5665\/sleep.5846","article-title":"Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects","volume":"39","author":"Osorio","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib148","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.12841","article-title":"The key role of insomnia and sleep loss in the dysregulation of multiple systems involved in mood disorders: a proposed model","volume":"28","author":"Palagini","year":"2019","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13825","article-title":"Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment","author":"Palagini","year":"2023","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib150","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13628","article-title":"Sleep, insomnia and mental health","volume":"31","author":"Palagini","year":"2022","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib151","first-page":"2866","article-title":"Orexin might predict status of alcohol dependence","volume":"131","author":"Pan","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.neuropharm.2023.109815_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108151","article-title":"Causal relationships between substance use and insomnia","volume":"214","author":"Pasman","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2023.109815_bib153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2003.09.032","article-title":"Increased hypocretin-1 levels in cerebrospinal fluid after REM sleep deprivation","volume":"995","author":"Pedrazzoli","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib154","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/mds.25197","article-title":"Sleep and Parkinson's disease: a review of case-control polysomnography studies: sleep and Parkinson's Disease","volume":"27","author":"Peeraully","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2023.109815_bib155","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1177\/0333102417727535","article-title":"Perceived triggers of primary headache disorders: a meta-analysis","volume":"38","author":"Pellegrino","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib156","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.smrv.2014.03.007","article-title":"Sleep and Alzheimer's disease","volume":"19","author":"Peter-Derex","year":"2015","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib157","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JHD-2012-120006","article-title":"Hypothalamic and limbic system changes in Huntington's disease","volume":"1","author":"Peters\u00e9n","year":"2012","journal-title":"J. Huntingt. Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in Huntington's disease","volume":"14","author":"Peters\u00e9n","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2023.109815_bib159","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib160","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13665","article-title":"The orexin story, sleep and sleep disturbances","volume":"31","author":"Pizza","year":"2022","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib161","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.copsyc.2019.10.005","article-title":"Insomnia in personality disorders and substance use disorders","volume":"34","author":"Provencher","year":"2020","journal-title":"Curr. Opin. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib162","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.eplepsyres.2016.02.014","article-title":"Insomnia in epilepsy is associated with continuing seizures and worse quality of life","volume":"122","author":"Quigg","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib163","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/head.13357","article-title":"Sleep and migraine: assessment and treatment of comorbid sleep disorders","volume":"58","author":"Rains","year":"2018","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.neuropharm.2023.109815_bib164","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neurol.2010.03.021","article-title":"\u00c9tude des liens entre sommeil et m\u00e9moire \u00e9pisodique chez le sujet jeune et \u00e2g\u00e9, et dans la maladie d'Alzheimer","volume":"166","author":"Rauchs","year":"2010","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neuropharm.2023.109815_bib165","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1528-1167.2008.01990.x","article-title":"Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures","volume":"50","author":"Rejdak","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2023.109815_bib166","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41386-019-0486-5","article-title":"Sleep disturbance in PTSD and other anxiety-related disorders: an updated review of clinical features, physiological characteristics, and psychological and neurobiological mechanisms","volume":"45","author":"Richards","year":"2020","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib167","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1389-9457(08)70004-2","article-title":"Insomnia and comorbid psychiatric disorders","volume":"8","author":"Riemann","year":"2007","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib168","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13604","article-title":"Insomnia disorder: state of the science and challenges for the future","volume":"31","author":"Riemann","year":"2022","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib169","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1474-4422(15)00021-6","article-title":"The neurobiology, investigation, and treatment of chronic insomnia","volume":"14","author":"Riemann","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib170","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","article-title":"CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions","volume":"57","author":"Ripley","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib171","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.06.008","article-title":"Hyperarousal in insomnia and hypnotic dose escalation","volume":"23","author":"Roehrs","year":"2016","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib172","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1084\/jem.20141788","article-title":"Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease","volume":"211","author":"Roh","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib173","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1016\/S1353-8020(08)70035-X","article-title":"Hypocretin-1 and secondary signs in Huntington's disease","volume":"13","author":"Roos","year":"2007","journal-title":"Parkinsonism Relat. Disorders"},{"key":"10.1016\/j.neuropharm.2023.109815_bib174","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5665\/sleep.5444","article-title":"Orexin receptor antagonism improves sleep and reduces seizures in Kcna1 -null mice","volume":"39","author":"Roundtree","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib175","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/B978-0-444-64032-1.00025-4","article-title":"Polysomnography","author":"Rundo","year":"2019"},{"key":"10.1016\/j.neuropharm.2023.109815_bib176","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrn3837","article-title":"The role of orexin in motivated behaviours","volume":"15","author":"Sakurai","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib177","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.conb.2013.04.007","article-title":"Orexin deficiency and narcolepsy","volume":"23","author":"Sakurai","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib178","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109815_bib179","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","article-title":"The orexin system: roles in sleep\/wake regulation: orexin and sleep\/wake state","volume":"1200","author":"Sakurai","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib180","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0166-2236(00)02002-6","article-title":"The sleep switch: hypothalamic control of sleep and wakefulness","volume":"24","author":"Saper","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib181","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1468-2982.2008.01566.x","article-title":"Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid","volume":"28","author":"Sarchielli","year":"2008","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib182","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuropharm.2018.09.034","article-title":"The role of the orexin system in stress response","volume":"154","author":"Sargin","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109815_bib183","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib184","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib185","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12423","article-title":"Epigenetics at the crossroads between genes, environment and resilience in anxiety disorders","volume":"17","author":"Schiele","year":"2018","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2023.109815_bib186","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0333102414537725","article-title":"Migraine and restless legs syndrome: a systematic review","volume":"34","author":"Sch\u00fcrks","year":"2014","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.neuropharm.2023.109815_bib187","first-page":"487","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J. Clin. Sleep Med. JCSM Off. Publ. Am. Acad. Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib188","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/psyg.12191","article-title":"Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study","volume":"17","author":"Scoralick","year":"2017","journal-title":"Psychogeriatr. Off. J. Jpn. Psychogeriatr. Soc."},{"key":"10.1016\/j.neuropharm.2023.109815_bib189","series-title":"Lemborexant: First Approval 15808 Bytes","author":"Scott","year":"2020"},{"key":"10.1016\/j.neuropharm.2023.109815_bib190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1513\/AnnalsATS.201608-625OC","article-title":"Insomnia, sleep quality, and quality of life in mild to moderate Parkinson's disease","volume":"14","author":"Shafazand","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.neuropharm.2023.109815_bib191","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0000000000000499","article-title":"Assessment of suvorexant and eszopiclone as alternatives to benzodiazepines for treating insomnia in patients with major depressive disorder","volume":"45","author":"Shigetsura","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib192","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3233\/JAD-190958","article-title":"Positive association between cognitive function and cerebrospinal fluid orexin A levels in Alzheimer's disease","volume":"73","author":"Shimizu","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib193","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2174\/156720512804142840","article-title":"Association between hypocretin-1 and amyloid-\u03b242 cerebrospinal fluid levels in Alzheimer's disease and healthy controls","volume":"9","author":"Slats","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib194","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lfs.2016.02.075","article-title":"SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice","volume":"150","author":"Soca\u0142a","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173466","article-title":"Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans","volume":"220","author":"Stoops","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109815_bib196","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13311-017-0602-3","article-title":"Targeted orexin and hypothalamic neuropeptides for migraine","volume":"15","author":"Strother","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2023.109815_bib197","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14728214.2012.693158","article-title":"Update on emerging drugs for insomnia","volume":"17","author":"Sullivan","year":"2012","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib198","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib199","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0269881115609015","article-title":"Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects","volume":"29","author":"Sun","year":"2015","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neuropharm.2023.109815_bib200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajp.2017.05.007","article-title":"Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia","volume":"28","author":"Suzuki","year":"2017","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109815_bib201","first-page":"1","article-title":"Sleep disturbances associated with Parkinson's disease","volume":"2011","author":"Suzuki","year":"2011","journal-title":"Park. Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib202","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/brainsci9120371","article-title":"Co-morbid insomnia and sleep apnea (COMISA): prevalence, consequences, methodological considerations, and recent randomized controlled trials","volume":"9","author":"Sweetman","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib203","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.smrv.2016.04.004","article-title":"Developing a successful treatment for co-morbid insomnia and sleep apnoea","volume":"33","author":"Sweetman","year":"2017","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib204","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/sleep\/28.11.1457","article-title":"Epidemiology of insomnia, depression, and anxiety","volume":"28","author":"Taylor","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.neuropharm.2023.109815_bib205","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson's disease","volume":"130","author":"Thannickal","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2023.109815_bib206","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109815_bib207","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/17482960802315024","article-title":"CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis","volume":"10","author":"Van Rooij","year":"2009","journal-title":"Amyotroph Lateral Scler."},{"key":"10.1016\/j.neuropharm.2023.109815_bib208","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1152\/physrev.00046.2019","article-title":"Brain mechanisms of insomnia: new perspectives on causes and consequences","volume":"101","author":"Van Someren","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib209","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mdc3.12899","article-title":"Practical evaluation and management of insomnia in Parkinson's disease: a review","volume":"7","author":"Wallace","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2023.109815_bib210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnmol.2018.00220","article-title":"The orexin\/receptor system: molecular mechanism and therapeutic potential for neurological diseases","volume":"11","author":"Wang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib211","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.sleep.2010.03.012","article-title":"Sleep maintenance insomnia complaints predict poor CPAP adherence: a clinical case series","volume":"11","author":"Wickwire","year":"2010","journal-title":"Sleep Med."},{"key":"10.1016\/j.neuropharm.2023.109815_bib212","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2869.2012.01027.x","article-title":"Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?: Sleepiness in Parkinson's disease","volume":"21","author":"Wienecke","year":"2012","journal-title":"J. Sleep Res."},{"key":"10.1016\/j.neuropharm.2023.109815_bib213","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.02.006","article-title":"Paradoxical function of orexin\/hypocretin circuits in a mouse model of Huntington's disease","volume":"42","author":"Williams","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109815_bib214","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.neuro.24.1.429","article-title":"To eat or to sleep? Orexin in the regulation of feeding and wakefulness","volume":"24","author":"Willie","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia: development of orexin receptor antagonists for insomnia","volume":"171","author":"Winrow","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109815_bib216","doi-asserted-by":"crossref","first-page":"11439","DOI":"10.1523\/JNEUROSCI.3459-04.2004","article-title":"Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response","volume":"24","author":"Winsky-Sommerer","year":"2004","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib217","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","article-title":"Orexin receptor antagonists and insomnia","volume":"24","author":"Wu","year":"2022","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib219","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/ejn.13323","article-title":"Orexin-A increases the activity of globus pallidus neurons in both normal and parkinsonian rats","volume":"44","author":"Xue","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11916-017-0641-9","article-title":"Sleep in patients with chronic migraine","volume":"21","author":"Yang","year":"2017","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.neuropharm.2023.109815_bib221","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","article-title":"Suvorexant: first global approval","volume":"74","author":"Yang","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2023.109815_bib222","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2014.00036","article-title":"Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls","volume":"8","author":"Yeoh","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109815_bib223","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14656566.2021.1902987","article-title":"Evaluating lemborexant for the treatment of insomnia","volume":"22","author":"Zammit","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2023.109815_bib224","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.6614","article-title":"Effect of suvorexant vs placebo on total daytime sleep hours in shift workers: a randomized clinical trial","volume":"3","author":"Zeitzer","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2023.109815_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2020.101281","article-title":"Sleep in Parkinson's disease: a systematic review and meta-analysis of polysomnographic findings","volume":"51","author":"Zhang","year":"2020","journal-title":"Sleep Med. Rev."},{"key":"10.1016\/j.neuropharm.2023.109815_bib226","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","article-title":"The prevalence of neuropsychiatric symptoms in Alzheimer's disease: systematic review and meta-analysis","volume":"190","author":"Zhao","year":"2016","journal-title":"J. Affect. Disord."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823004057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823004057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:50:21Z","timestamp":1719971421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823004057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":226,"alternative-id":["S0028390823004057"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109815","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109815"}}